In situ engineered blood vessels – body own blood vessels with no foreign material left in the body after 28 days
VACIS’ technology uses a synthetic rod, which is inserted under the skin and induces the formation of a new, fully functional blood vessel. After approximately 28 days implantation, the rod-like device is removed leaving in place an in-situ formed vessel of fibrocollagenous tissue with a high burst pressure.
Johan van den Arend Schmidt
With VACIS since spin off in 2016 and experienced international CEO with extensive biotech knowledge and experience Previous/current held positions at: CEO CapGemini Consulting Partner PwC UK Founder/investor several biotechs Executive Director Severn Trent The Boston Consulting Group Education: Master Biochemical Technology Delft University Master Business Administration Rotterdam Erasmus University
Harrie van Baars
Chief Medical Officer
Harrie van Baars is a medical professional with deep experience in (vascular) Medical Devices Previous/current held positions at: Board of Directors SPL Medical CEO NonWoTecc Medical GmbH CEO Gelita Medical MD Schering-Plough Education: MD Medicine University of Nijmegen NIMA A, B, C Marketing Finance for non financial executives INSEAD
Chief Financial Officer
With VACIS since 2016 as CFO and office manager Previous/current held positions at: ASM Partners Citigroup investment banking Salomon Brothers investment banking ABN Amro bank corporate finance Education: Chartered Financial Analyst (CFA) Master Financial Economy VU University Bachelor Business Administration Nijenrode University
Head of Production
With VACIS since 2016 (initially as trainee) Previous/current held positions at: Coriolis Pharma PTRL Europe System Pharmacology Leiden Acadamic Centre for Drug Research Education: Biopharmaceutical Sciences Leiden University Bachelor of Science Technical University Munich
Steef Hermans is graduating from Hogeschool Zuyd in 2018 and will be supporting the ISO13485 certification process as part of this final traineeship Previously held positions at: Chemelot Inovation and Learning Labs (CHILL) at Brightlands Chemelot Campus Lab technician MagnaMedics Diagnostics Education: Applied Science, specialization Material Science Zuyd University ROC Leeuwenborgh
Lab technician (contractor)
Celeste Tillemans is lab technician and with VACIS since end 2017 Previously held positions at: Biomedical Technician InSciTe Brightlands Campus Chemelot Innovation and Learning Labs (CHILL) at Brightland Campus PathoFinder Education: Applied Science Zuyd University
With VACIS since October 2016 as undergraduate student Previously held positions at: European Pharmaceutical Students' Association Royal Dutch Pharmaceutical Students' Association Division of Pharmacology, Leiden Academic Centre for Drug Research, Leiden University Education: Bachelor Bio- Pharmaceutical Sciences, Leiden University
Former Intern at the MERLN Institute for Technology-Inspired Regenerative Medicine of Maastricht University Previously held positions at: Chemelot Inovation and Learning Labs at Brightlands Chemelot Campus, Zuyd University Education: Graduating BSc. Applied Science, specialization Material Science
- VACIS is the leading tissue engineering company for body-own blood vessels
- VACIS develops in situ tissue engineered blood vessels providing novel therapeutic options for vascular surgery. Prosthetic vascular graft failure is a frequent complication in vascular surgery with substantial morbidity and health care costs. VACIS provides patients autologous graft vessels, with sustained patency and fewer complications requiring less corrective interventions.
- Vascular grafts are needed in many areas of medicine. VACIS initially focuses on vascular access in patients undergoing hemodialysis. Other indications will follow after clinical validation of the technology in hemodialysis. Such other indications include peripheral arterial occlusive disease.
- VACIS provides an advantage over other therapeutic options in the hemodialysis access market. Current solutions have a low patency: many arteriovasculair fistulas fail to mature or no adequate vein is available; the foreign material in synthetic grafts lead to infection, stenosis, thrombosis etc. and the synthetic material does not heal after cannulation.